To assess the efficacy and safety of twice-daily administration of nedocromil sodium 2% ophthalmic solution, we performed a multicenter study involving 140 patients with seasonal allergic conjunctivitis. Subjects had a history of seasonal allergic conjunctivitis and positive results of a skin test to ragweed. The trial coincided with the peak ragweed pollen season at five treatment centers. Patients treated with nedocromil sodium had improvements in symptoms with statistically significant reductions recorded for eye itching (P ≤ .04), conjunctival injection (P ≤ .001), and overall disease severity (P ≤ .001) as compared to the placebo-treated group. Adverse events were minor and transient. We concluded that nedocromil sodium 2% ophthalmic solution administered twice daily is effective in relieving major symptoms associated with seasonal allergic conjunctivitis.
Bibliographical noteFunding Information:
From the Department of Medicine, University of Minnesota, Minneapolis, Minnesota (Drs. Blumenthal and Kaiser); Department of Internal Medicine, University of Iowa Hospitals, Iowa City, Iowa (Drs. Casale and Smith); Department of Medicine, University of Kansas School of Medicine, Prairie Village, Kansas (Dr. Dockhorn); and Clinical Research Unit (Dr. Jarmoszuk) and Max Samter Institute of Allergy and Clinical Immunology (Dr. Zeitz), Grant Hospital of Chicago, Chicago, Illinois. This study was supported by a grant from Fisons Pharmaceuticals.